Results 91 to 100 of about 21,216 (279)

Raltegravir: molecular basis of its mechanism of action

European Journal of Medical Research, 2009
Integration of the HIV-1 viral DNA generated by reverse transcription of the RNA genome into the host cell chromosomes is a key step of viral replication, catalyzed by the viral integrase.
Mouscadet Jean-François, Tchertanov Luba   +1 more
doaj   +1 more source

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients [PDF]

, 2011
Objectives To compare the frequency of previously in vitro-selected integrase mutations (T124A, T124A/S153F, S153Y, T124A/S153Y and L101I/T124A/S153Y) conferring resistance to S/GSK1349572 between HIV-1 subtype B integrase inhibitor (INI)-naive and ...
Armenia, D, Calvez, V, Ceccherini-Silberstein, F, Fabeni, L, Fourati, S, Katlama, C, Malet, I, Marcelin, A, Masquelier, B, Perno, CF, Sayon, S, Wirden, M   +11 more
core   +1 more source

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study

AIDS Research and Therapy, 2020
Background In resource-limited settings, multi-experienced HIV infected patients are often prescribed raltegravir for salvage therapy. Patients failing raltegravir-containing regimens require other drugs including other integrase inhibitors.
Aurelio Orta-Resendiz, R. Rodriguez-Diaz, Luis A. Angulo-Medina, M. Hernandez-Flores, L. Soto-Ramírez   +4 more
semanticscholar   +1 more source

Discovery of a Baloxavir‐Inspired Endonuclease Inhibitor That Prevents Herpes Simplex Virus 1 Replication in Cell Culture and In Vivo

Advanced Science, Volume 12, Issue 42, November 13, 2025.
Current herpesvirus treatments targeting the viral DNA polymerase are limited by toxicities and drug resistance. Novel compounds inhibiting the nuclease activity of the herpes simplex virus 1 (HSV‐1) terminase complex, required for viral genome packaging, have been identified.
Sabina Andreu, Kai Tang, Jiahui Zhou, Gabriel Pino‐Peco, Nerea López‐Carrobles, Raquel Bello‐Morales, Daniel Galdo‐Torres, Lina Zhang, Federico Gago, José Antonio López‐Guerrero, Xinyong Liu, Peng Zhan, Luis Menéndez‐Arias   +12 more
wiley   +1 more source

Antiretroviral therapy containing raltegravir to prevent mother-to-child transmission of HIV in infected pregnant women

Infectious Disease Reports, 2017
We conducted a retrospective study in a general hospital in Buenos Aires, Argentina (2009-2015) aimed at evaluating outcomes in HIV-infected pregnant women (HIPW), who were prescribed raltegravir (RAL)- containing antiretroviral therapy (ART). A total of
Diego M. Cecchini, Marina G. Martinez, Laura M. Morganti, Claudia G. Rodriguez   +3 more
doaj   +1 more source

Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes [PDF]

, 2011
The activity of raltegravir and 4 other integrase inhibitors (MK-2048, L870,810, IN2, and IN5) was investigated in primary human macrophages, PBMC and C8166-lymphocytic T cells, in order to determine their relative potency and efficacy in different ...
Aquaro, S, Ceccherini-Silberstein, F, Perno, C, Pollicita, M, Santo, F, Scopelliti, F, Surdo, M   +6 more
core   +1 more source

Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

Clinical Pharmacology &Therapeutics, EarlyView.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

Clinical Evaluation of Drug–Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P‐gp Pathways

The Journal of Clinical Pharmacology, Volume 65, Issue 11, Page 1420-1432, November 2025.
Abstract In addition to antiretroviral therapy (ART), people with HIV often take medications to treat comorbidities. It is therefore important to assess these medications for potential drug‐drug interactions, which may affect the safety and efficacy of ART. Three phase I studies were conducted in adult participants without HIV. The pharmacokinetics (PK)
Priyanka Arora, Hui Liu, John Ling, Jason T. Hindman, Dhananjay D. Marathe   +4 more
wiley   +1 more source

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection

Infection and Drug Resistance, 2010
Lisa M Chirch, Roy T SteigbigelDivision of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USAAbstract: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a ...
Lisa M Chirch, Roy T Steigbigel
doaj  

Are new antiretroviral treatments increasing the risks of clinical obesity?

Journal of Virus Eradication, 2019
There is growing evidence that the use of integrase inhibitors could lead to statistically significant increases in body weight and even clinical obesity, although it is unclear whether these changes are clinically significant.
Andrew Hill, Laura Waters, Anton Pozniak
doaj   +1 more source